STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Rhea-AI Summary
Gilead Sciences, Inc. announces $12.6 million grant funding for 19 organizations to improve HIV landscape for Black women and girls in the U.S. as part of Setting the P.A.C.E. initiative. The grants aim to increase HIV prevention, anti-stigma efforts, and health equity for Black cisgender and Transgender women and girls disproportionately impacted by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Rhea-AI Summary
Gilead Sciences, Inc. announces FDA approval for Biktarvy to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Biktarvy is now the first and only INSTI-based single-tablet regimen approved for this specific group, providing a high barrier to resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
fda approval
-
News

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Rhea-AI Summary
Gilead Sciences, Inc. announces new clinical data and real-world evidence at CROI 2024, showcasing commitment to advancing antiviral research. Studies cover HIV treatment, COVID-19 impact, and Hepcludex safety in HIV/HBV/HDV coinfection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
News

Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change

Rhea-AI Summary
National Black HIV/AIDS Awareness Day's theme 'Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities' highlighted by Gilead grantee, the National Black Leadership Commission on Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
News

Gilead Sciences to Present at Upcoming Investor Conferences

Rhea-AI Summary
Gilead Sciences, Inc. (GILD) executives will be speaking at various investor conferences in March. The conferences include TD Cowen Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Annual Global Healthcare Conference. The webcasts can be accessed on the company's investors page with replays available for 30 days post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
-
News

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Rhea-AI Summary
Gilead Sciences, Inc. has been named one of America's Most JUST Companies, ranking fifth in the Pharmaceuticals and Biotech industry. The company's commitment to stakeholder engagement, sustainability, and creating a healthier world has been recognized. Gilead's ESG strategy focuses on health equity, access to medicines, inclusive workplace, and environmental sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
News

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces promising results of opaganib in treating radiation-induced lung inflammation and fibrosis. Opaganib, a selective SPHK2 inhibitor, significantly improved long-term survival in an in vivo mouse model post ionizing radiation exposure. The data suggest its potential as a medical countermeasure for radiation and cancer therapy. Opaganib is being evaluated for Acute Radiation Syndrome (ARS) and other indications like COVID-19, ARDS, filoviruses, and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News

Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies

Rhea-AI Summary
Gilead Sciences' innovative antiviral therapies have revolutionized the treatment of chronic hepatitis C, leading to high cure rates and transforming millions of lives globally. The company's commitment to providing low-cost treatments to vulnerable populations has been instrumental in efforts to eliminate the disease by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
-
News

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Rhea-AI Summary
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to add seladelpar, a PPARδ agonist for the treatment of Primary Biliary Cholangitis (PBC), with FDA priority review and anticipated US approval in the third quarter of 2024. Seladelpar Phase 3 data showcases a best-in-disease profile for second-line PBC, expanding Gilead's liver disease portfolio and commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
acquisition
News

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Rhea-AI Summary
Gilead Sciences, Inc. has been recognized as one of America's Most JUST Companies, ranking fifth in the Pharmaceuticals and Biotech industry. The company's commitment to stakeholder engagement, sustainability, and creating a healthier world has been highlighted. Gilead's ESG strategy focuses on health equity, access to medicines, inclusive workplace, and environmental sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY